Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Lifecore Biomedical, Inc.NASDAQ: LFCR

EBITDA · Q3 FY2026 · quarter ended Mar 2026

EBITDA of -$5.28M in Q3 FY2026

Q3 FY2026 EBITDA was -$5.28M. Trailing-twelve-month EBITDA was -$1.03M.

Context

  • EBITDA amounted to 6.8% of revenue in FY2025, down 20.9 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$95.31K (+98.9%) for the fiscal year ending May 2026, a step up from the -124.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.28M-204.4% QoQ
Last fiscal yearMay 2025
-$8.81M-124.8% YoY
LTMMar 2026
-$1.03M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-124.8%+98.9%+223.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(8.81M) USD
Year-over-year change
-124.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • EBITDA amounts to 0.8% of revenue for LFCR, versus a peer median of 71.8%.
LFCR Competitors
EBITDA for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$10.48M CAD-79.6%—3.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$1.03M USD——0.8%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$9.96M USD+38.2%—23.8%
SGHTSight Sciences, Inc.LTM Mar 2026-$31.68M USD+27.7%—39.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
CVRXCVRx, Inc.LTM Mar 2026-$45.97M USD-0.0%—77.8%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$50.86M USD-14.6%——
IMMPImmutep LimitedFY2025-A$62.88M AUD-41.2%—1246.6%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.21M USD-28.4%—864.8%
CGCCanopy Growth CorporationLTM Mar 2026-CA$205.34M CAD+57.2%—65.7%
Peer median (excluding LFCR) —-14.6%—71.8%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.